Supplementary Figure 2: The TIGIT ligand CD155 is abundant in human and murine tumors. | Nature Immunology

Supplementary Figure 2: The TIGIT ligand CD155 is abundant in human and murine tumors.

From: Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

Supplementary Figure 2

(a) Representative images of immunolabeling for CD155 and CD112 in human tumor tissues (paraffin sections from 20 tumor patients with colorectal cancer or lung cancer). Scale bars are 100 μm. (b) The expression of CD155 and CD112 on tumor cells we used in the murine tumor models. (a, b) The experiment was repeated independently for four times with similar results.

Back to article page